Tarsus Pharmaceuticals, Inc. (TARS)
71.79
-0.13
(-0.18%)
USD |
NASDAQ |
Aug 28, 16:00
71.79
0.00 (0.00%)
After-Hours: 20:00
Tarsus Pharmaceuticals Cash from Operations (Quarterly) : 61.22M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 61.22M |
| March 31, 2026 | -24.65M |
| December 31, 2025 | 19.33M |
| September 30, 2025 | 18.26M |
| June 30, 2025 | -29.39M |
| March 31, 2025 | -20.65M |
| December 31, 2024 | -22.18M |
| September 30, 2024 | -8.652M |
| June 30, 2024 | -14.40M |
| March 31, 2024 | -37.79M |
| December 31, 2023 | -39.34M |
| September 30, 2023 | -32.36M |
| June 30, 2023 | -23.83M |
| March 31, 2023 | -21.97M |
| Date | Value |
|---|---|
| December 31, 2022 | -10.87M |
| September 30, 2022 | -18.61M |
| June 30, 2022 | -4.259M |
| March 31, 2022 | -15.29M |
| December 31, 2021 | -12.12M |
| September 30, 2021 | 7.112M |
| June 30, 2021 | 20.55M |
| March 31, 2021 | -11.79M |
| December 31, 2020 | -10.01M |
| September 30, 2020 | -6.572M |
| June 30, 2020 | -2.557M |
| March 31, 2020 | -1.996M |
| December 31, 2019 | -0.806M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Structure Therapeutics, Inc. | -120.38M |
| Alumis, Inc. | -81.50M |
| Veradermics, Inc. | -14.49M |
| ANI Pharmaceuticals, Inc. | 56.67M |
| Corcept Therapeutics, Inc. | 33.54M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 37.88M |
| Cash from Financing (Quarterly) | 3.302M |
| Free Cash Flow | 56.00M |
| Free Cash Flow Per Share (Quarterly) | 1.317 |
| Free Cash Flow to Equity (Quarterly) | 57.17M |
| Free Cash Flow to Firm (Quarterly) | 59.68M |
| Free Cash Flow Yield | 1.82% |